Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Citi raises Santen Pharma shares target on new drug prospects

EditorEmilio Ghigini
Published 05/24/2024, 04:22 PM
© Reuters.
SNPHY
-

On Friday, Citi updated its outlook on Santen Pharmaceutical Co (OTC:SNPHY)., Ltd (4536:JP) (OTC: SNPHF) shares, increasing the price target to ¥2,400 from the previous ¥2,000, while maintaining a Buy rating on the stock. This adjustment comes in the wake of the company's full-year results and the anticipation of new drug releases.

The company's financial estimates for the fiscal year ending March 2025 have been adjusted to account for domestic drug price revisions and the impact of an increase in co-pays for long-listed drugs starting in October. Despite these changes, the guidance provided by Santen Pharmaceutical is considered by the analyst to be on the conservative side.

Citi has revised its forecasts following the successful development of two treatments: the myopia treatment DER-127 and the blepharoptosis treatment STN138. Both are expected to launch in 2025, with peak annual sales projections increased to ¥30 billion each, up from the previous estimate of ¥20 billion.

The upward revision in the price target is attributed to the roll forward of the base year and an increase in medium-term forecasts, stemming from higher sales estimates for these new drugs.

The analyst notes that both treatments will be sold in Japan outside the insurance system, at patients' own expense. This market, which is not bound by insurance limitations, is seen as a potential area for domestic growth for Santen Pharmaceutical.

The company's strategy to tap into the own-expense market is significant as it allows for revenue streams that are not restricted by insurance requirements, providing a potential boost to the company's growth prospects in Japan.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.